Home / News & Insights / Whistleblower Law Insights / TAP Pharmaceuticals to pay $150 million to settle drug overcharge case

TAP Pharmaceuticals to pay $150 million to settle drug overcharge case

TAP Pharmaceuticals will pay $150 million to settle claims it overcharged consumers and private insurers for Lupron, a drug used to treat prostate cancer, endometriosis and premature puberty.

TAP had paid the government $885 million in 2001 to resolve charges that it participated in a criminal conspiracy by providing doctors with free samples of Lupron for which Medicare was billed.

The current settlement was reported on in the December 2, 2004 issue of the Boston Globe.

Let us help you.
Get a free, confidential case review